Yamamoto, Nobuyuki

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 3,228

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,574

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,002

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 750

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 377

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

Maruyama, R., Nishiwaki, Y., Tamura, T., Yamamoto, N., Tsuboi, M., Nakagawa, K., Shinkai, T., Negoro, S., Imamura, F., Eguchi, K., et al. (2008) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 367

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

Schuler, M., Wu, Y.-L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., Popat, S., Sequist, L. V., Massey, D., Zazulina, V., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 361

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Katakami, N., Atagi, S., Goto, K., Hida, T., Horai, T., Inoue, A., Ichinose, Y., Koboyashi, K., Takeda, K., Kiura, K., et al. (2013) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 326

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Yang, J. C.-H., Sequist, L. V., Zhou, C., Schuler, M., Geater, S. L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K., et al. (2016) · Annals of Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 194

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Shiraishi, Y., Kishimoto, J., Sugawara, S., Mizutani, H., Daga, H., Azuma, K., Matsumoto, H., Hataji, O., Nishino, K., Mori, M., et al. (2024) · JAMA Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 54